

# Ashley S Margol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3850743/publications.pdf>

Version: 2024-02-01

41  
papers

1,046  
citations

623734

14  
h-index

434195

31  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, 1964-1975.	1.2	15
2	MEDB-86. A re-induction regimen for children with recurrent medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i126-i127.	1.2	1
3	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. <i>Neuro-Oncology</i> , 2022, 24, i117-i117.	1.2	0
4	Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	1.5	1
5	IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature. <i>Brain Pathology</i> , 2021, 31, e12959.	4.1	7
6	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29172.	1.5	3
7	Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab037.	0.7	3
8	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 785-796.	1.2	18
9	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 944-954.	1.2	25
10	Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28516.	1.5	5
11	A genome-wide association study on medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 309-315.	2.9	10
12	Primary diffuse leptomeningeal glioneuronal tumors of the central nervous system: Report of three cases and review of literature. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 248-258.	0.8	17
13	Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10525-10525.	1.6	24
14	NURS-09. INTRODUCTION OF A WELLNESS PROGRAM FOR PEDIATRIC NEURO-ONCOLOGY PROVIDERS. <i>Neuro-Oncology</i> , 2020, 22, iii422-iii422.	1.2	0
15	OTHR-09. CENTRAL DIABETES INSIPIDUS: A RARE UNREPORTED SIDE EFFECT OF TEMOZOLOMIDE IN PEDIATRICS. <i>Neuro-Oncology</i> , 2020, 22, iii423-iii424.	1.2	0
16	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. <i>Neuro-Oncology</i> , 2020, 22, iii332-iii332.	1.2	0
17	Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series. <i>Cureus</i> , 2020, 12, e10804.	0.5	4
18	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. <i>Journal of Neuro-Oncology</i> , 2019, 145, 375-383.	2.9	7

#	ARTICLE	IF	CITATIONS
19	Clinical and neuropsychological outcome of pediatric non-midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27983.	1.5	9
20	Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo <sup>1</sup> H-MR Spectroscopy. <i>American Journal of Neuroradiology</i> , 2019, 40, 872-877.	2.4	6
21	Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. <i>Oncotarget</i> , 2019, 10, 551-557.	1.8	44
22	Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. <i>Journal of Neuro-Oncology</i> , 2018, 138, 199-207.	2.9	7
23	Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002576.	1.2	8
24	MBCL-49. PROGNOSTIC SIGNIFICANCE OF MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IN CHILDREN RECEIVING IRRADIATION-SPARING REGIMENS. <i>Neuro-Oncology</i> , 2018, 20, i128-i128.	1.2	0
25	A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group. <i>Journal of Neuro-Oncology</i> , 2018, 140, 575-582.	2.9	9
26	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. <i>Journal of Neuro-Oncology</i> , 2017, 133, 119-128.	2.9	32
27	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017, 134, 705-714.	7.7	168
28	Palliative Care Options for a Young Adult Patient with a Diffuse Intrinsic Pontine Glioma. <i>Cureus</i> , 2017, 9, e1580.	0.5	5
29	AT-02MR SPECTROSCOPY AND METABOLIC SUBTYPES OF ATYPICAL TERATOID RHABDOID TUMORS IN CHILDREN. <i>Neuro-Oncology</i> , 2016, 18, iii1.1-iii1.	1.2	0
30	AT-23ENCOURAGING SURVIVAL OF PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID AND RHABDOID TUMOR (AT/RT) TREATED AS PER CHILDREN'S ONCOLOGY GROUP ACNS0333 STUDY: A SINGLE-INSTITUTION EXPERIENCE. <i>Neuro-Oncology</i> , 2016, 18, iii6.3-iii6.	1.2	0
31	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	1.5	94
32	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , 2016, 8, 366ra161.	12.4	144
33	NU-12THE USE OF AROMATHERAPY TO REDUCE CHEMOTHERAPY-INDUCED NAUSEA IN CHILDREN WITH CANCER; A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL. <i>Neuro-Oncology</i> , 2016, 18, iii137.2-iii137.	1.2	0
34	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2016, 18, 126-131.	1.2	69
35	Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3090-3097.	3.2	56
36	Pediatric Brain Tumor Cell Lines. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 218-224.	2.6	50

#	ARTICLE	IF	CITATIONS
37	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. <i>Clinical Cancer Research</i> , 2015, 21, 1457-1465.	7.0	92
38	Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined By Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3725-3725.	1.4	2
39	Pathology and diagnosis of SMARCB1-deficient tumors. <i>Cancer Genetics</i> , 2014, 207, 358-364.	0.4	81
40	<i>PID1</i> ( <i>NYGGF4</i> ), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 827-836.	7.0	29
41	Influenza vaccine immunization in a pediatric oncology ambulatory practice.. <i>Journal of Clinical Oncology</i> , 2013, 31, 139-139.	1.6	1